Drug Price Trends for LYRICA

Average Pharmacy Cost for LYRICA

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
LYRICA 150 MG CAPSULE	00071-1016-41	9.68883	EACH	2025-03-19
LYRICA 100 MG CAPSULE	00071-1015-68	9.69740	EACH	2025-03-19
LYRICA 150 MG CAPSULE	00071-1016-68	9.68883	EACH	2025-03-19
LYRICA 150 MG CAPSULE	58151-0240-32	9.68883	EACH	2025-03-19
LYRICA 100 MG CAPSULE	00071-1015-41	9.69740	EACH	2025-03-19

Market Analysis and Price Projections for Pregabalin (LYRICA)

Introduction to Pregabalin (LYRICA)

Pregabalin, marketed under the brand name Lyrica, is a medication used to treat a variety of neurological and psychiatric conditions, including epilepsy, neuropathic pain, anxiety disorders, and fibromyalgia. Here’s a comprehensive analysis of the pregabalin market, including its current state, growth projections, and key factors influencing its market dynamics.

Market Size and Growth Projections

The global pregabalin market is anticipated to experience significant growth over the coming years. Here are some key statistics:

• The pregabalin market was valued at $1.6 billion in 2022 and is projected to reach $2.2 billion by 2032, growing at a CAGR of 3% from 2023 to 2032[4].
• Another forecast indicates that the market will register a CAGR of 5% during the period from 2025 to 2030[1].

Key Drivers of Market Growth

Several factors are driving the growth of the pregabalin market:

High Prevalence of Epilepsy and Related Disorders

Epilepsy affects over 50 million individuals worldwide, with 80% of this population residing in low- and middle-income countries. The World Health Organization estimates that up to 70% of people living with epilepsy could avoid seizures with proper diagnosis and care. This high prevalence and the increasing awareness about the disease are expected to increase the demand for effective treatments like pregabalin[1][4].

Expanding Applications

Pregabalin is used in the management and treatment of various conditions, including neuropathic pain, anxiety disorders, and fibromyalgia. The extensive application of pregabalin in treating these ailments is a significant growth factor for the market[3].

Launch of Generic Versions

The introduction of generic pregabalin products is anticipated to drive market growth due to their cost-effectiveness and increased availability. For example, in May 2022, Lupin Pharmaceuticals received FDA approval for its ANDA for pregabalin capsules in various dosages, which is expected to boost market growth[1].

Regional Market Analysis

North America

North America is expected to hold the largest market share in the pregabalin market during the forecast period. The high prevalence of epilepsy in the United States, along with the strong presence of key market players and new product approvals, are driving factors for this region. For instance, the US FDA approved Zydus' Pregabalin Capsules in December 2022, which is expected to contribute to market growth in North America[1].

Asia Pacific

The Asia Pacific region is estimated to be the fastest-growing market for pregabalin. The increasing awareness about neurological disorders and the growing demand for effective treatments in this region are key factors driving this growth[1][4].

Distribution Channels

The market is segmented based on distribution channels, with drug stores and retail pharmacies dominating the market share in terms of revenue. However, the online providers segment is anticipated to grow at the fastest CAGR during the forecast period, reflecting the increasing trend of online pharmacy services[4].

Product Forms

The tablets and capsules segment dominated the pregabalin market in terms of revenue and is expected to grow at the fastest CAGR during the forecast period. This is due to the ease of administration and the wide acceptance of these forms among patients[4].

Challenges and Restraints

Despite the growth prospects, the pregabalin market faces several challenges:

Alternative Treatments

The availability of alternative treatments for neurological and psychiatric conditions can restrain the growth of the pregabalin market. Patients and healthcare providers may opt for other medications or therapies, reducing the demand for pregabalin[1].

Adverse Effects

Pregabalin is associated with adverse effects such as dizziness, drowsiness, and weight gain, which can deter some patients from using it. This could impact market growth negatively[1].

Regulatory Policies

Stringent regulatory policies can also act as a restraint. The process of obtaining approvals and the strict guidelines for drug manufacturing and marketing can slow down the introduction of new pregabalin products to the market[1].

Price Projections and Cost Savings

Impact of Generic Versions

The launch of generic pregabalin products is expected to reduce the overall cost of the medication, making it more accessible to a wider population. Generic versions are typically priced lower than their branded counterparts, which can lead to significant cost savings for patients[1].

Medicare Price Negotiation

The Biden-Harris Administration's initiatives to negotiate drug prices under Medicare are expected to lower the out-of-pocket costs for patients. While pregabalin is not currently listed among the drugs selected for Medicare price negotiation, similar initiatives could potentially impact the pricing of pregabalin in the future, especially if it is included in future negotiations[2][5].

Key Players

The pregabalin market is dominated by several key players, including:

• Teva Pharmaceuticals
• Cipla Limited
• Medley Pharmaceuticals Limited
• Viatris Inc.
• Amneal Pharmaceuticals LLC[1].

These companies are actively involved in the development, manufacturing, and marketing of pregabalin products, contributing to the market's growth.

Key Takeaways

• The pregabalin market is expected to grow significantly, driven by the high prevalence of epilepsy and related disorders.
• The launch of generic pregabalin products will increase market accessibility and reduce costs.
• North America holds the largest market share, while the Asia Pacific region is the fastest-growing market.
• The market faces challenges from alternative treatments, adverse effects, and stringent regulatory policies.
• Distribution channels are shifting towards online providers, and tablets and capsules remain the dominant product forms.

FAQs

What is the current market size of the pregabalin market?

The global pregabalin market was valued at $1.6 billion in 2022 and is projected to reach $2.2 billion by 2032[4].

What is the expected CAGR of the pregabalin market from 2025 to 2030?

The pregabalin market is expected to register a CAGR of 5% during the forecast period from 2025 to 2030[1].

Which region is expected to grow at the highest CAGR in the pregabalin market?

The Asia Pacific region is estimated to grow at the highest CAGR during the forecast period[1][4].

What are the primary growth drivers for the pregabalin market?

The high prevalence of epilepsy and related disorders, the launch of generic versions, and the expanding applications of pregabalin are primary growth drivers[1][3][4].

Who are the major players in the pregabalin market?

Major players include Teva Pharmaceuticals, Cipla Limited, Medley Pharmaceuticals Limited, Viatris Inc., and Amneal Pharmaceuticals LLC[1].

How will the launch of generic pregabalin products impact the market?

The launch of generic pregabalin products is expected to increase market accessibility and reduce costs, driving market growth due to their cost-effectiveness and increased availability[1].